License and Collaboration Agreements - Additional Information (Details) |
1 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Oct. 24, 2023 |
Nov. 30, 2025
USD ($)
|
Dec. 31, 2021
USD ($)
|
May 31, 2021
USD ($)
Agreements
|
Jan. 31, 2020
USD ($)
shares
|
Dec. 31, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
Dec. 31, 2021
USD ($)
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Research and development expense | $ 133,720,000 | $ 112,473,000 | ||||||
| Accounts payable | $ 5,306,000 | 4,624,000 | ||||||
| National Institutes of Health | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Collaboration, option and license agreement, description | Under the NIH Agreements, commencing in January 2023 and subsequently on January 1 of each calendar year thereafter, the Company is also required to make minimum annual royalty payments of $0.2 million, which shall be credited against any earned royalties due based on a low single-digit percentage of net sales made in a respective year. In addition, benchmark royalties following the completion of certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a product reaching FDA approval or foreign-equivalent approval totaling $5.7 million for the autologous patent license agreement and $1.7 million for the allogeneic patent license agreement. Additional benchmark royalties would be payable for a subsequent indication under each NIH Agreement. If the Company enters into a sublicensing agreement, it will be required to pay the NIH a sublicense royalty payment as a percentage of the fair market value of any consideration received for each sublicense granted. The sublicensing percentage starts at a high teens to low twenties percentage if clinical trials for the product have not yet begun and decreases to a mid-single-digit percentage if the product has received FDA approval or foreign-equivalent approval. | |||||||
| Intellia Therapeutics, Inc. | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Collaboration, option and license agreement, description | Under the Intellia Agreement, Intellia owns rights, title and interests in and to any intellectual property developed in the course of performance under the Intellia Agreement that is not specifically directed to the CRISPR Product. The Company granted to Intellia certain non-exclusive, royalty-free, fully paid-up, worldwide licenses under the Company’s intellectual property solely to perform the activities designated to Intellia under the collaboration, and to research, develop or otherwise exploit any human therapeutic product that is developed or commercialized by Intellia, utilizes or incorporates Intellia intellectual property and that is not the CRISPR Product or any product directed to CD19 or any other B-cell antigen.In addition, the Company granted Intellia an exclusive option (the “Intellia Option”) to enter into a co-development and co-commercialization agreement with the Company for the CRISPR Product, (the “Co-Co Agreement”) for a fee payable to the Company. If Intellia exercises the Intellia Option, the Company and Intellia would share equally the regulatory and clinical development expenses associated with obtaining approval of the CRISPR Product in the U.S. and would also share equally all net profits and losses from commercialization of the CRISPR Product in the U.S. If Intellia exercises the Intellia Option, no milestone payments will be due and payable from that time forward and the Company will only pay royalties on sales outside of the U.S. In addition, upon exercise of the Intellia Option, following regulatory approval of the CRISPR Product, Intellia will have exclusive commercialization rights for the CRISPR Product for U.S. administration, subject to the Company’s rights to co-promote the CRISPR Product in the U.S., and the Company will retain the sole and exclusive rights to research, develop, or otherwise exploit the CRISPR Product for rest-of-world administration and shall have sole decision-making authority in relation thereto, subject to the parties’ obligations to cooperate regarding certain development, regulatory and commercialization strategies. | |||||||
| Kite Pharma, Inc. | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Collaboration, option and license agreement, description | Pursuant to the Kite Agreement, the Company was also obligated to pay mid-teen-and mid-single-digit percentages of annual maintenance fees, minimum annual royalties and patent prosecution costs payable under the UCSF License Agreement. The Company was also obligated to pay a $6.3 million sublicensing fee under the UCSF License Agreement, which the Company agreed to offset with future milestone payments payable by Gilead under the Gilead Agreement.The Company had the sublicensing fee of $6.3 million payable presented as current accrued license expense—related party in the balance sheet as of December 31, 2024. In October 2025, the Company, Gilead and Kite agreed to settle the outstanding balance as follows: 1) a payment of $2.5 million in cash within 30 days; 2) the remaining balance of $3.8 million to settle no later than December 31, 2026, through an issuance of common stock at market price, a cash payment, or any combination of both cash payment and common stock issuance, at the discretion of the Company. The parties also agreed to terminate the Kite Agreement and released one another from any further obligations.The Company paid $2.5 million in November 2025 and the remaining balance of $3.8 million is presented as current accrued license expense – related party in the balance sheet as of | |||||||
| Patent License Agreements | National Institutes of Health | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Minimum annual royalty payments | $ 200,000 | |||||||
| Number of agreements | Agreements | 2 | |||||||
| Acquired licenses, amount paid | $ 3,300,000 | |||||||
| Research and development expense | $ 200,000 | 200,000 | ||||||
| Royalties payable | 0 | 0 | ||||||
| Accounts payable | 0 | 600,000 | ||||||
| Patent License Agreements | Research and Development Expense | National Institutes of Health | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Acquired licenses, amount paid | $ 3,300,000 | |||||||
| Research and development expense | 0 | 600,000 | ||||||
| Patent License Agreements | Autologous Patent License Agreement | National Institutes of Health | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Cumulative royalty due | 5,700,000 | |||||||
| Patent License Agreements | Allogeneic Patent License Agreement | National Institutes of Health | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Cumulative royalty due | $ 1,700,000 | |||||||
| License and Collaboration Agreement | Intellia Therapeutics, Inc. | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Milestone payments | 0 | 0 | ||||||
| License and Collaboration Agreement | Intellia Therapeutics, Inc. | Maximum | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Milestone payments | $ 64,500,000 | |||||||
| License and Collaboration Agreement | Intellia Therapeutics, Inc. | Series B Preferred Stock | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Temporary equity shares issued, fair value | $ 7,000,000 | |||||||
| Collaboration, Option and License Agreement | Gilead Sciences, Inc. | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Number of days of notice period for terminating agreement | 90 days | |||||||
| Kite License Agreement | Kite Pharma, Inc. | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Sublicensing fee | $ 6,300,000 | |||||||
| Kite License Agreement | Kite Pharma, Inc. | Accrued License Expense, Related Party | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Sublicensing fee | $ 2,500,000 | 3,800,000 | $ 6,300,000 | |||||
| Kite License Agreement | Kite Pharma, Inc. | Maximum | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Milestone payments | $ 10,800,000 | |||||||
| Kite License Agreement | Kite Pharma, Inc. | Series A-2 Redeemable Convertible Preferred Stock | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Shares issued | shares | 4,042,066 | |||||||
| Kite License Agreement | Gilead Sciences, Inc. and Kite Pharma, Inc. | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Outstanding sublicensing fee agreed to settle in cash | 2,500,000 | |||||||
| Remaining outstanding sublicensing fee agreed to pay | $ 3,800,000 | |||||||
| Stock Purchase Agreement | Gilead Sciences, Inc. | Series A-2 Redeemable Convertible Preferred Stock | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Shares issued | shares | 6,890,744 | |||||||